SMARCE1 is required for the invasive progression of in situ cancers

SMARCE1 is required for the invasive progression of in situ cancers

Advances in mammography have sparked an exponential increase in the detection of early-stage breast lesions, most commonly ductal carcinoma in situ (DCIS). More than 50% of DCIS lesions are benign and will remain indolent, never progressing to invasive cancers. However, the factors that promote DCIS...

Full description

Bibliographic Details
Main Authors: Feng, Yu-Xiong (Author), Tizabi, Minu D. (Author), Cohen, Malkiel A. (Author), Sanduja, Sandhya (Author), Reinhardt, Ferenc (Author), Pandey, Jai (Author), Sokol, Ethan Samuel (Contributor), Jin, Dexter X. (Contributor), Miller, Daniel Handel (Contributor), Superville, Daphne A. (Contributor), Jaenisch, Rudolf (Contributor), Gupta, Piyush (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: National Academy of Sciences (U.S.), 2018-01-18T17:31:27Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items